IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Commentary & News
Archived Headlines
- Gene therapy biotech Lexeo Therapeutics files for a $100 million IPO 09/29/23
- Skincare company Elevai Labs files and sets terms for an $8 million IPO 09/29/23
- Former foreign-listed companies migrate to US exchanges as IPO market stirs 09/29/23
- Cancer biotech Adlai Nortye prices US IPO at $23 09/29/23
- Early-stage esports firm Gamer Pakistan prices IPO at $4, the low end of the range 09/29/23
See more
US IPO Week Ahead: Government shutdown looms over October IPO market
The October IPO market looks like it will be off to a quiet start, with no IPOs currently scheduled for the week ahead. The impending US government shutdown means it could stay that way. Leading the week’s potential headlines, luxury sandal brand Birkenstock (BIRK) is reportedly set to launch its US IPO on the first Monday of the month, with plans to price...read more
US IPO Weekly Recap: Holdover Adlai Nortye leads 4 IPO week as more small deals enter the pipeline
The third quarter wrapped up with four IPOs and eight pipeline additions. Oncology biotech Adlai Nortye (ANL) raised $58 million at an $849 million market cap. The company originally planned to raise $72 million in August but never priced; it removed and then set new terms earlier this month. Operating through subsidiaries in the US and China, Adlai...read more
Cancer biotech Kairos Pharma files for an estimated $10 million IPO
Kairos Pharma, a Phase 2 biotech developing therapies for cancer, filed on Friday with the SEC for an initial public offering. The company did not disclose a proposed deal size, but we estimate the company could raise around $10 million. Kairos Pharma is focused on advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug...read more
French chronic disease biotech Abivax files for a $100 million US IPO
Abivax, a late-stage French biotech developing therapies for chronic inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company is currently listed on the Euronext Paris under the symbol "ABVX". Abivax is focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the...read more